Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsJubilant life science

    Jubilant Life Science

    Jump to

    • Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct

      Net Sales are expected to increase by 17.8 percent Y-o-Y (up 7.4 percent Q-o-Q) to Rs. 2,436.5 crore, according to ICICI Direct.

    • Jubilant Life Sciences Limited Q2 & H1’FY19 Earnings Conference Call

      This is the verbatim transcript of Jubilant Life Sciences management call with analysts.

    • Jubilant Life Science Q2 PAT seen up 96.5% YoY to Rs. 250 cr: HDFC Securities

      Net Sales are expected to increase by 30.1 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs. 2,140 crore, according to HDFC Securities.

    • Jubilant Life Science Q2 PAT seen up 65.6% YoY to Rs. 212.4 cr: ICICI Direct

      Net Sales are expected to increase by 27.3 percent Y-o-Y (up 0.6 percent Q-o-Q) to Rs. 2,090.3 crore, according to ICICI Direct.

    • Jubilant Life Sciences Q3 net up 80 percent to Rs 212.84 crore

      Jubilant Life Sciences said in a BSE filing that the company had posted a net profit of Rs 118.11 crore for the corresponding period of the previous fiscal.

    • Buy Reliance Industries, Torrent Power, Strides Shasun; sell Union Bank of India: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Reliance Industries, Torrent Power and Strides Shasun and can sell Union Bank of India.

    • Buy Jubilant Life Sciences: Prakash Gaba

      Prakash Gaba of prakashgaba.com suggests buying Jubilant Life Sciences.

    • Look at RPP Infra, VRL, Rallis, Capital First: Dilip Bhat

      Dilip Bhat of Prabhudas Lilladher is of the view that one may look at RPP Infra Projects, VRL Logistics, Rallis India and Capital First.

    • Bull's Eye: Buy Britannia, Sintex, Bharti Infratel, Apollo Tyre, UPL

      Vijay Chopra of enochventures.com advises buying Apollo Tyre with a target of Rs 21.

    • Hold Jubilant Life Science;target of Rs 460: ICICI Direct

      Karvy has recommended hold rating on Jubilant Life Science with a target price of Rs 460 in its research report dated November 3, 2015.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347